v3.20.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Revenue:    
Grant and licensing revenue $ 3,049,104 $ 5,793,849
Operating expenses:    
Research and development 13,013,604 16,233,014
General and administrative 9,431,015 7,025,212
Goodwill impairment loss 737,000  
Change in fair value of contingent consideration 613,290 495,936
Total operating expenses 23,794,909 23,754,162
Loss from operations (20,745,805) (17,960,313)
Interest income 431,824 265,752
Other (expense) income, net (25,557) 117,780
Total non-operating income 406,267 383,532
Net loss before income taxes (20,339,538) (17,576,781)
Income tax (expense) benefit (45,178) 985,488
Net loss (20,384,716) (16,591,293)
Net loss - non-controlling interest (367,148) (857,439)
Net loss attributable to Heat Biologics, Inc. $ (20,017,568) $ (15,733,854)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.60) $ (0.90)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 33,281,817 17,485,461
Other comprehensive loss:    
Net loss $ (20,384,716) $ (16,591,293)
Unrealized gain on foreign currency translation 8,654 146,121
Total other comprehensive loss (20,376,062) (16,445,172)
Comprehensive loss attributable to non-controlling interest (367,148) (857,439)
Comprehensive loss $ (20,008,914) $ (15,587,733)

Source